Zoetis Inc. (NYSE:ZTS) is a top healthcare stock to buy, with a $130 price target and Hold rating by Stifel Nicolaus. Piper Sandler downgraded ZTS to Neutral with a $135 target, citing an innovation gap. Morgan Stanley cut the target to $160, citing alpha-generation opportunities in healthcare and headwinds in managed care.

Zoetis Inc. (NYSE:ZTS) is a New Jersey-based provider of animal health products established in 1950. While ZTS shows investment potential, other AI stocks may offer better upside. For more on undervalued AI stocks, check out a free report on the best short-term AI stock.

Read more at Yahoo Finance: Zoetis Inc. (ZTS) Sees Mixed Analyst Sentiment as Targets Are Trimmed